TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37304846

Group type: EXPERIMENTAL
Intervention: Weekly iron and folic acid (WIFA) supplementation and menstrual hygiene management (MHM) support for girls
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Behavior change interventions to improve nutrition, MHM, and WASH knowledge
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Survey assessing nutrition, MHM, and WASH knowledge and experience
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Micronutrient status measurement
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: WASH infrastructure observation
Number of subjects: 2244
Study: 37305080

Group type: EXPERIMENTAL
Intervention: Starch thickened formula with reduced lactose content, probiotics and prebiotics, administered for 30 days.
Number of subjects: 101
Study: 37305082

Group type: EXPERIMENTAL
Intervention: Maternal preconception BMI and gestational weight gain (CGWG)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Maternal conditional GWG (CGWG)
Number of subjects: 864
Study: 37305429

Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride and metformin hydrochloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metformin hydrochloride
Number of subjects: 120
Study: 37305610

Group type: EXPERIMENTAL
Intervention: Nurse-led decision counseling program plus usual care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 20
Study: 37306039

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 1-3 months of DAPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study: 37306107

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg orally on Days 1-21 and ganitumab 18 mg/kg intravenously on Days 1 and 15 of a 28-day cycle.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg daily for 21 days (after dose reduction due to DLTs).
Number of subjects: 10
Study: 37306128

Group type: EXPERIMENTAL
Intervention: PrEP initiation at private pharmacies
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PrEP continuation at 1 month
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PrEP continuation at 4 months
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PrEP continuation at 7 months
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Pill coverage
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Acceptability of pharmacy-delivered PrEP services
Number of subjects: 287
Study: 37306288

Group type: COMPARATOR
Intervention: BAY1128688 (3, 30, or 90 mg once daily or 60 mg twice daily for 14 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BAY1128688 (60 mg once or twice daily for 28 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 37306407

Group type: EXPERIMENTAL
Intervention: HELIOS stent
Number of subjects: 3060
Study: 37306430

Group type: EXPERIMENTAL
Intervention: Tele-PFMT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home-PFMT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 37306636

Group type: EXPERIMENTAL
Intervention: Troponin-only Manchester Acute Coronary Syndromes decision aid
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: History, ECG, Age, Risk Factors, Troponin
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: History and ECG-only Manchester Acute Coronary Syndromes decision aid
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: History, ECG, Age, Risk Factors
Number of subjects: 817
Study: 37306637

Group type: EXPERIMENTAL
Intervention: Recalibrated HEART score less or equal to 3
Number of subjects: 3752

Group type: COMPARATOR
Intervention: Original HEART score less or equal to 3
Number of subjects: 3752

Group type: EXPERIMENTAL
Intervention: Recalibrated TIMI score less or equal to 1
Number of subjects: 3752

Group type: COMPARATOR
Intervention: Original TIMI score less or equal to 1
Number of subjects: 3752

Group type: EXPERIMENTAL
Intervention: Nonischemic ECG with hs-cTn T less than LOD/LOQ
Number of subjects: 3752

Group type: COMPARATOR
Intervention: Nonischemic ECG with hs-cTn T below the 99th percentile
Number of subjects: 3752
Study: 37306717

Group type: EXPERIMENTAL
Intervention: Avacopan (CCX168)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 37306720

Group type: EXPERIMENTAL
Intervention: High-medium adherence (80-100%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low adherence (0-79%)
Number of subjects: 18
Study: 37306763

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping
Number of subjects: 17
Study: 37306813

Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
Number of subjects: 21
Study: 37306874

Group type: EXPERIMENTAL
Intervention: Seeking Safety (integrated treatment for gambling and PTSD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Pathological Gambling (for gambling alone)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 65
Study: 37307001

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg orally once a day for 12 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo orally once a day for 12 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 37307005

Group type: EXPERIMENTAL
Intervention: Add-on Rehmannia-6-based Chinese medicine treatment for 48 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Add-on Rehmannia-6-based Chinese medicine treatment
Number of subjects: 148
Study: 37307078

Group type: EXPERIMENTAL
Intervention: OSAUS assessment tool
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EULAR assessment tool
Number of subjects: 30
Study: 37307142

Group type: EXPERIMENTAL
Intervention: 6-minute minimal examination time
Number of subjects: 1926

Group type: COMPARATOR
Intervention: Baseline examination time
Number of subjects: 1926
Study: 37307232

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 μg kg -1 bolus followed by 0.4 μg kg -1 h -1 maintenance until dural closure)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 37307310

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37307514

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by Nivolumab 3 mg/kg once every 2 weeks for ≤24 months
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab followed by Nivolumab monotherapy
Number of subjects: 533
Study: 37307519

Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Village Health Clubs (VHC)
Number of subjects: 2806

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2806
Study: 37307528

Group type: EXPERIMENTAL
Intervention: Poliprotect (5 times a day for the initial 2 weeks and on demand thereafter)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Omeprazole (20 mg q.d.)
Number of subjects: 275
Study: 37307537

Group type: EXPERIMENTAL
Intervention: Video-based feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional feedback
Number of subjects: 22
Study: 37307844

Group type: EXPERIMENTAL
Intervention: Inoculation with 10 50% tissue culture infectious dose of pre-alpha wild-type SARS-CoV-2 (Asp614Gly) by intranasal drops.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Coriolis air samples
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mask samples
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hand swabs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surface swabs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Symptom scores collected using self-reported symptom diaries
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Timing of emissions
Number of subjects: 36
Study: 37307902

Group type: EXPERIMENTAL
Intervention: Blue-light imaging (BLI)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 901

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 901
Study: 37308042

Group type: EXPERIMENTAL
Intervention: On-site training arm (TRA)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: No on-site training arm (NO-TRA)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1158
Study: 37308076

Group type: EXPERIMENTAL
Intervention: Home-based blood pressure management supported by community blood pressure monitors and a mobile health application (CBPM arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: An identical strategy to the CBPM arm using a cellular blood pressure cuff (eCBPM+ arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC arm) clinic-based management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 0
Study: 37308133

Group type: EXPERIMENTAL
Intervention: Antibiotics (C1 group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No antibiotics (C2 group)
Number of subjects: 55
Study: 37308218

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once a day
Number of subjects: 3209

Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week with concomitant methotrexate (MTX)
Number of subjects: 3209

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 3209
Study: 37308251

Group type: EXPERIMENTAL
Intervention: Y-2 sublingual tablet
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study: 37308268

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 37308285

Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular shift surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Diagnostic arthroscopy alone
Number of subjects: 68
Study: 37308342

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg daily
Number of subjects: 83
Study: 37308396

Group type: EXPERIMENTAL
Intervention: cfDNA level at diagnosis ≥ or <30 ng/mL and presence or not of KRAS-mutated ctDNA at D28
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: cfDNA level at diagnosis and presence of KRAS-mutated ctDNA at D28
Number of subjects: 65
Study: 37308490

Group type: EXPERIMENTAL
Intervention: JMT101 plus osimertinib 160 mg
Number of subjects: 121
Study: 37308679

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for SUD
Number of subjects: 76
Study: 37308751

Group type: EXPERIMENTAL
Intervention: Double dose of once-weekly insulin icodec
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Triple dose of once-weekly insulin icodec
Number of subjects: 163

Group type: COMPARATOR
Intervention: Double dose of once-daily insulin glargine U100
Number of subjects: 163

Group type: COMPARATOR
Intervention: Triple dose of once-daily insulin glargine U100
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 163

Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 163
Study: 37308874

Group type: EXPERIMENTAL
Intervention: Persons with PD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched persons without PD)
Number of subjects: 20
Study: 37308905

Group type: EXPERIMENTAL
Intervention: Liberal fluid infusion group (Ringer's lactate solution, maintaining PPV within 6-9%)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Restrictive fluid infusion group (maintaining PPV within 13-16%)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 97
Study: 37308969

Group type: EXPERIMENTAL
Intervention: Active PEMF treatment and eccentric exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment and eccentric exercise
Number of subjects: 40
Study: 37308971

Group type: EXPERIMENTAL
Intervention: Xentuzumab (1000 mg weekly intravenous infusion) with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Number of subjects: 101
Study: 37309006

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) for 12 weeks
Number of subjects: 336

Group type: COMPARATOR
Intervention: Psychoeducation program (Ending Self-Stigma) for 12 weeks
Number of subjects: 336

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Psychoeducation program (Ending Self-Stigma)
Number of subjects: 336
Study: 37309193

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (DW1903) daily for 2 weeks
Number of subjects: 476

Group type: COMPARATOR
Intervention: Famotidine 20 mg (DW1903R1) daily for 2 weeks
Number of subjects: 476
Study: 37309249

Group type: EXPERIMENTAL
Intervention: Belly roll (Bero) protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37309365

Group type: EXPERIMENTAL
Intervention: Octocog alfa (BAY 81-8973) prophylaxis
Number of subjects: 113

Group type: COMPARATOR
Intervention: rFVIII-FS prophylaxis
Number of subjects: 113
Study: 37309696

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) defined as serum ferritin < 100 μg/L or ferritin 100-299 μg/L with transferrin saturation < 20%.
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Routine laboratory examinations for diagnosing ID.
Number of subjects: 461
Study: 37309702

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib (COMBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vemurafenib (VEMU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Encorafenib (ENCO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: COMBO, VEMU, ENCO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COMBO
Number of subjects: 0
Study: 37310015

Group type: EXPERIMENTAL
Intervention: Robotic enhanced-view totally extraperitoneal (eTEP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Robotic intraperitoneal onlay mesh (rIPOM)
Number of subjects: 100
Study: 37310058

Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 exposure (553 patients)
Number of subjects: 3350

Group type: COMPARATOR
Intervention: Patients without COVID-19 exposure (2797 patients)
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: 2022 cohort (80% patients with COVID-19 history)
Number of subjects: 3350

Group type: COMPARATOR
Intervention: 2018 cohort
Number of subjects: 3350

Group type: EXPERIMENTAL
Intervention: Postoperative pulmonary complications
Number of subjects: 3350
Study: 37310119

Group type: EXPERIMENTAL
Intervention: Dendrimer PET tracer
Number of subjects: 0
Study: 37310167

Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Radical resection (RR)
Number of subjects: 266
Study: 37310174

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Face-Mask Continuous Positive Airway Pressure (CPAP)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Helmet Continuous Positive Airway Pressure (CPAP)
Number of subjects: 159
Study: 37310224

Group type: EXPERIMENTAL
Intervention: INLAIs (specifically BDM-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDM-2
Number of subjects: 0
Study: 37310243

Group type: EXPERIMENTAL
Intervention: Appropriate post-CCTA management
Number of subjects: 14232

Group type: COMPARATOR
Intervention: Inappropriate post-CCTA management
Number of subjects: 14232
Study: 37310246

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary and exercise counseling (Control)
Number of subjects: 0
Study: 37310308

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin (AVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37310306

Group type: EXPERIMENTAL
Intervention: Managed Transition (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 37310329

Group type: EXPERIMENTAL
Intervention: 6-week CBT-I via a smartphone application
Number of subjects: 320
Study: 37310391

Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on anti-CD20
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on fingolimod
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on other treatments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Delayed booster vaccination in MS patients on anti-CD20
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination in MS patients on other treatments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination in MS patients on anti-CD20
Number of subjects: 90
Study: 37310415

Group type: EXPERIMENTAL
Intervention: Phytochemicals from herbs/spices consumed in a meal
Number of subjects: 24
Study: 37310492

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Specific sham mindfulness
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: General sham mindfulness
Number of subjects: 169

Group type: COMPARATOR
Intervention: Audiobook control
Number of subjects: 169
Study: 37310776

Group type: EXPERIMENTAL
Intervention: Positive communication group
Number of subjects: 249

Group type: COMPARATOR
Intervention: Negative communication (nocebo) group
Number of subjects: 249

Group type: COMPARATOR
Intervention: Neutral communication (neutral) group
Number of subjects: 249
Study: 37310781

Group type: EXPERIMENTAL
Intervention: Self-guided digital training (DT) course
Number of subjects: 262

Group type: COMPARATOR
Intervention: Digital training (DT) course with weekly individualized coaching
Number of subjects: 262
Study: 37310790

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 22
Study: 37310872

Group type: COMPARATOR
Intervention: Dantu heterozygotes
Number of subjects: 141

Group type: COMPARATOR
Intervention: Dantu homozygotes
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Non-Dantu subjects
Number of subjects: 141
Study: 37310877

Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional dosing interval
Number of subjects: 174
Study: 37310983

Group type: EXPERIMENTAL
Intervention: Mobile technology interventions (iBreast Exam device, mobile breast ultrasound, mobile mammography) and patient navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast cancer awareness education (Control group)
Number of subjects: 0
Study: 37311055

Group type: EXPERIMENTAL
Intervention: Bevacizumab, Temsirolimus, and Valproic Acid
Number of subjects: 47
Study: 37311111

Group type: EXPERIMENTAL
Intervention: Emotion-focused skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37311173

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 13
Study: 37311202

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37311248

Group type: EXPERIMENTAL
Intervention: Acute hypoxia exposure
Number of subjects: 0
Study: 37311429

Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Number of subjects: 0
Study: 37311468

Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0 mg/kg body weight subcutaneously every 3 weeks, titrated up to 1.75 mg/kg)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Epoetin alfa (450 IU/kg body weight subcutaneously once a week, titrated up to 1050 IU/kg)
Number of subjects: 356
Study: 37311694

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-coated patch
Number of subjects: 227

Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 227
Study: 37311720

Group type: EXPERIMENTAL
Intervention: Behavioural lifestyle interventions (dietary changes, physical activity, moderate weight loss)
Number of subjects: 685
Study: 37311722

Group type: EXPERIMENTAL
Intervention: Danuglipron (200 mg BID)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Danuglipron (low [5-mg] or high [10-mg] starting dose, escalating to 80, 120 or 200 mg BID)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 37311823

Group type: EXPERIMENTAL
Intervention: CHA
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Baseline CHA
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Follow-up CHA
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Delta CHA
Number of subjects: 1127
Study: 37312017

Group type: EXPERIMENTAL
Intervention: High women's empowerment
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Empowerment-based interventions targeting women's decision-making and control over assets
Number of subjects: 1609
Study: 37312021

Group type: EXPERIMENTAL
Intervention: Delirium patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-delirium patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 37312053

Group type: EXPERIMENTAL
Intervention: HYDRA proton- and photon radiotherapy (40 Gy elective dose, 55 Gy simultaneous integrated boost, 59 Gy focal boost)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (not specified)
Number of subjects: 100
Study: 37312054

Group type: EXPERIMENTAL
Intervention: 3 cycles of anti-PD-1 immunotherapy with avelumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care (not explicitly detailed in the abstract)
Number of subjects: 58
Study: 37312079

Group type: EXPERIMENTAL
Intervention: Digital Human Avatars (DHA) using multi-omics data and clinical factors
Number of subjects: 600
Study: 37312086

Group type: EXPERIMENTAL
Intervention: non-standard targeted therapy based on potentially actionable molecular alterations or biomarkers
Number of subjects: 500
Study: 37312095

Group type: EXPERIMENTAL
Intervention: β-lactoglobulin supplementation with resistance exercise training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carbohydrate (dextrose) control with resistance exercise training
Number of subjects: 24